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doi:10.1016/j.jds.2012.03.006Abstract Background/purpose: Oral squamous cell carcinoma (OSCC) is a prevalent cancer
worldwide. Recent data suggest that a subpopulation of cancer cells, termed cancer stem cells
(CSCs), is capable of initiating, maintaining, and expanding the growth of tumors. Importantly,
CSCs confer chemo- and radioresistance. Cisplatin is the most widely used chemotherapeutic
agent, and chemoresistance to cisplatin is one of the major causes of tumor recurrence and
metastasis with OSCC. However, the role of oral-cancer stem-like cells (OC-SLCs) in the che-
moresistance of OSCC has not determined. The aim of this study was to investigate a key player
of chemoresistance in OC-SLCs.
Materials and methods: OC-SLCs were isolated through sphere formation by cultivating the
OC2 cell line in defined serum-free medium. Differential expression profiles of cell-surface
stemness markers between enriched OC-SLCs and parental OSCC cells were elucidated by flow
cytometry. Expression of excision repair cross-complementation group 1 (ERCC1) by OC-SLCs
was examined by an RT-PCR and Western blotting.
Results: Initially, significant sphere formation (OC-SLCs) was observed in OC2 cells. Enriched
OC-SLCs highly expressed stem-cell surface markers (CD117 and CD133) and the ABC trans-
porter gene (ABCG2). Enhanced chemoresistance to cisplatin was also noted in OC-SLCs.
Further, the chemoresistance of OC-SLCs to cisplatin was possibly correlated with ERCC1 upre-
gulation in OC-SLCs.ntistry, College of Oral Medicine, Chung Shan Medical University, 110 Chien-Kuo N. Road, Section 1,
(M.-Y. Chou).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
112 L.-L. Tsai et alConclusions: In summary, these results suggest that OC-SLCs may play a vital role in tumor
recurrence due to resistance to cisplatin. Additionally, ERCC1 upregulation might be involved
in platinum resistance in oral CSCs.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most
prevalent malignancy worldwide and the third most
common cancer in developing nations.1,2 A prognosis of
OSCC remains dismal because > 50% of patients die from
this disease or complications within 5 years under current
therapies.3 In the last several years, accumulating
evidence has lent support to the idea that human cancer
can be considered a stem-cell disorder.4 According to the
hierarchical "stem-cell model of carcinogenesis," tumors
are not to be viewed as simple monoclonal expansions of
transformed cells, but rather as complex tissues where
abnormal growth is driven by a rare cancer stem-cell (CSC)
pool that acquires tumor-like features such as uncon-
trolled growth and also maintains its innate capacity to
self-renew and differentiate into phenotypically hetero-
geneous progeny.5 CSCs are also generally believed to
possess unique survival mechanisms.6 In view of their
stem-like properties, these cells are believed to be
responsible for maintaining and propagating the entire
tumor.7 Therefore, to completely eradicate a tumor and
prevent recurrence, it is imperative that CSCs be specifi-
cally targeted.8 In our previous study, we derived
a subpopulation of oral-cancer stem-like cells (OC-SLCs)
from OSCC with serum-free medium by sphere formation.9
The enriched OC-SLCs possess characteristics of both stem
cells and malignant tumors.9 However, the function of
OC-SLCs in chemoresistance in OSCC has not been
determined.
Platinum-based chemotherapy has been used for treat-
ing a wide variety of solid tumors including lung, head and
neck, ovarian, cervical, and testicular cancers for over 3
decades.10 Cisplatin predominantly interacts with DNA to
form intra-strand crosslinked DNA adducts which trigger
a series of intracellular events that ultimately result in cell
death.10e13 Although platinum therapy was a major
advance in improving patient outcomes, the emergence of
resistance limits the effectiveness of platinating agents in
solid tumors, including OSCC.10,11 Molecular mechanisms of
resistance are complex,10,11 but it is clear from recent
studies that the DNA-repair capacity may have a major
impact on resistance to cisplatin.14,15 DNA intra-strand
crosslinks are processed and repaired by the nucleotide
excision repair (NER) pathway in mammalian cells.16,17 To
address these critical clinical issues, several potential
predictive and prognostic markers were investigated. In
those studies, the excision repair cross-complementation
group (ERCC)1, a critical protein within the NER pathway,
was the focus. Evaluation of ERCC1 messenger (m)RNA
levels in tumor samples taken from patients in small
retrospective clinical trials of ovarian,18,19 colorectal,20,21
and non-small cell lung cancer showed an inversecorrelation with either the response to platinum therapy
or survival.22 Another study also showed a statistically
significant survival benefit in patients with low levels of
ERCC1 who had received platinum-based chemotherapy,
compared to patients with high levels of ERCC1 who had
received cisplatin chemotherapy.23
Patients generally die of cancer after current therapies
fail to eliminate residual disease. Due to the enhanced
tumorigenecity of CSCs, it was proposed that failure to
effectively treat cancer may be related to preferential
resistance of these CSCs to chemotherapeutic agents.
Evidence for chemoresistance by SLCs in epithelial cell lines
and xenogeneic tumor-derived cells was presented.24e26
Here, we demonstrated that the OC-SLCs generated from
an OSCC cell line had enhanced chemoresistance to
cisplatin, and the chemoresistance of OC-SLCs was possibly
correlated with ERCC1 upregulation. Our results imply
that mechanisms of resistance to platinum chemothera-
peutic agents in OC-SLCs might be attributed to ERCC1
upregulation.
Materials and methods
Cell line and isolation of OC-SLCs from OSCC
OC2 is a cell line derived from an OSCC specimen of
a buccal-mucosa squamous carcinoma from a Chinese man.
OC2 cells are tumorigenic in nude mice.27 Originally, OC2
cells were grown in RPMI supplemented with 10% fetal
bovine serum. The OC2 cell line was then cultured in tumor
sphere medium consisting of serum-free Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F-12, N2 supplement, 10 ng/
mL human recombinant basic fibroblast growth factor
(bFGF), and 10 ng/mL epidermal growth factor (EGF). Cells
were plated at a density of 7.5 104 live cells/10 cm dish,
and the medium was changed every other day until sphere
formation was observed in about 4 weeks.9,28,29
Fluorescence-activated cell sorting (FACS) analysis
For OC-SLC surface marker identification, a single-cell
suspension from trypsinized spheres was stained with
anti-CD133, CD117 (c-Kit), or ABCG2 and secondary FITC- or
phycoerythrin-coupled antibodies (MACS) and analyzed
with a FACS Calibur apparatus (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA).
Reverse-transcription polymerase chain reaction
(RT-PCR)
Total RNA of parental oral-cancer cells or derived OC-SLCs
was purified. Briefly, total RNA was obtained using
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SuperScript one-step RT-PCR with the Platinum Taq system
(Invitrogen) was carried out to analyze RNA molecules.
Reverse-transcription was performed at 50C for 30
minutes, and the PCR was performed with specific primers
in 50 ml volumes according to the protocol provided by the
manufacture (Invitrogen). Endogenous ERCC1 RNA mole-
cules were amplified using the forward primer, 50-GATGCC
AGAGACAGTGCCCCAAG-30, and reverse primer, 50-ACTA
CACAGGCTGCTGCTGCAGC-30. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control in
the RT-PCR with primers 50-CCACATCGCTCAGACACCAT-30
and 50-CCTCCGACGCCTGCTTCACCAC-30. The amplification
reaction involved denaturation at 95C for 15 seconds,
annealing at 55C for 30 seconds, and 72C for 90 seconds
using a thermal cycler (PTC-1000; MJ Research, St. Bruno,
Quebec, Canada). The resultant RT-PCR products were
analyzed on ethidium bromide-stained 1% agarose gels.
Western blot analysis
Cells were washed in phosphate-buffered saline (PBS) and
incubated in ice-cold lysis buffer containing a protease
inhibitor cocktail for 20 min. Equal amounts of protein
samples were subjected to sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and then trans-
ferred to a nitrocellulose membrane. The membrane was
soaked in buffer (50 mM Tris-HCl and 0.15 M NaCl; pH 7.3)
containing 5% low fat milk (Tris-milk) for 30 min with gentle
shaking. A strip of a nitrocellulose membrane was incu-
bated with a monoclonal antibody against ERCC1 (1:500
dilution in Tris-milk) for 4 h at room temperature and then
washed. Next, the strip was incubated with a goat anti-
mouse immunoglobulin G (IgG) antibody (1: 1000 dilution
on Tris-milk). The strip was washed again, and the reactive
bands were visualized using H2O2-chloronaphthol reagents.
b-Actin was used as a loading control.
Cytotoxicity assays: the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay
Cisplatin was obtained from Bristol Myers Squibb (Prince-
ton, NJ, USA). Cell viability was evaluated using the an MTT
conversion assay. Cells (104) were plated in 250 ml of
medium/well in 96-well plates (Costar, Corning, Rochester,
NY, USA). After overnight incubation, various concentra-
tions of cisplatin were added. After 24 h, 40 ml of 5 mg/ml
MTT was added per well. After 2 h of incubation, cells were
lysed with 100 ml/well of dimethyl sulfoxide (DMSO), and
incubated overnight. The absorbance was read at 550 nm in
a microplate reader (Bio-Rad, city?, ST?, USA). Cell survival
was expressed as the percentage of absorbance relative to
that of untreated cells.
Statistical analysis
The Statistical Package of Social Sciences software (SPSS,
Chicago, IL, USA) was used for the statistical analysis. An
independent Student’s t-test was used to compare contin-
uous variables between groups. The statistical significance
level was set to 0.05 for all tests.Results
Isolation and cultivation of OC-SLCs from OSCC cells
To investigate the existence of OC-SLCs in oral-cancers
cells, OC2, an oral cancer cell line, was cultured in defined
serum-free medium with bFGF and EGF. After being
cultured for 2 weeks, cancer cells gradually detached from
the culture dishes, aggregated, and formed sphere-like
bodies. Significant sphere-like bodies were observed after 3
weeks of serum-free medium culture (Fig. 1).
Characterization of progenitor/stem-cell
properties in isolated OC-SLCs
To further characterize the progenitor/stem-cell properties
of our enriched OC-SLCs, we used flow cytometry to detect
expression profiles of progenitor/stem-cell surface
markers. As shown in Fig. 2, we detected that the majority
of isolated OC-SLCs were positively stained with CD133 and
CD117 (c-Kit), both of which are specific cell-surface
markers of normal/tumor stem cells. We also detected
that most of the enriched OC-SLCs from OC2 cells were
ABCG2-positive (Fig. 2). Around 50% of OC-SLCs derived
from OC2 cells also stained positively for CD133, CD117,
and ABCG2.
Enhanced cisplatin resistance of isolated OC-SLCs
We monitored the chemoresistance of parental OSCC cells
and OC-SLCs by an MTT assay. We further tested common
chemotherapeutic agents against OSCC including cisplatin.
As presented in Fig. 3, compared to parental OSCC cells,
OC-SLCs were significantly resistant to cisplatin, which is
currently used for OSCC chemotherapy (*P< 0.05; Fig. 3).
Elevated expression of ERCC1 in OC-SLCs
To investigate key genes involved in mediating the che-
moresistance properties of OC-SLCs, transcriptional and
translational ERCC1 expressions were examined by an RT-
PCR and Western blotting. Total RNA of parental cells and
of sphere-like body cells enriched with 4 weeks of serum-
free medium culture from the OC2 cell line was purified.
The level of the ERCC1 transcript of enriched OC-SLCs
significantly increased compared to that of parental OC2
cells (Fig. 4A). In accordance with the RT-PCR results, the
Western blotting data also showed that the protein level of
ERCC1 was upregulated in enriched OC-SLCs (Fig. 4B).
Discussion
While a revolution in therapeutic strategies yielding
significant clinical responses measured in terms of tumor
regression and disease-free survival occurred in recent
decades, overall survival from OSCC has failed to substan-
tially improve.30 The recent identification of CSC subpop-
ulations with the unique ability to fuel tumor growth, may
shed light on the disconnect between response rates and
overall survival.31 These cells possess unique survival
Figure 2 Increased stem cell surface markers expression in OC-SLC. (A) Expression profiles of progenitor/stem cell-specific
surface markers including CD133, CD117, and ABCG2 in parental cells or derived OC-SLC were analyzed by flow cytometry.
Single-cell suspension from parental cells or derived OC-SLC was either stained with control IgG antibody or experimental anti-
bodies including anti-CD133 (left panel), CD117 (middle panel), and anti-ABCG2 (right panel); (B) Around 50% of OC-SLC derived
from OC2 cells stained positively with CD133, CD117 and ABCG2, respectively (*P< 0.05).
Figure 1 Sphere body formation in OC2. Oral cancer cell line OC2 was used and cultured in DMEM/F-12 serum-free medium with
bFGF and EGF. After being in culture for 3 weeks, cancer cells gradually detached from culture dishes, aggregated, and formed
sphere-like bodies (SB). Increase of the volume of sphere-like body from the OC-SLC was observed with longer cultivation
(4 weeks). Bottom right, magnification.
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Figure 3 Evaluation of cisplatin sensitivity in parental OSCCs
and OC-SLC. Both 10,000 parental OSCCs and OC-SLC were
plating in a 96-well plate and treated with various concentra-
tions of cisplatin for 24 hours in 10% FBS/DMEM/F-12 medium.
The survival rate was determined by MTT assay (*P< 0.05).
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the ability to self-renew and differentiate, and also exhibit
a marked ability to proliferate following a prolonged period
of quiescence.31 That is, therapies which fail to adequately
target CSC populations, which represent a minority of most
epithelial tumors, will fail to eliminate those cells capable
of regenerating the tumor after therapy has ceased.8
Furthermore, familiarity with both the means of resis-
tance to a particular chemotherapeutic agent and the
phenotypic identity of cells that harbor resistance mecha-
nisms should help facilitate the discovery of therapiesFigure 4 Enhanced ERCC1 expression in OC-SLC. (A) Total RNA w
elevated expression of ERCC1 gene in derived OC-SLC was detected
prepared from parental OC2 or sphere-like body cells and analyzed
indicated. The amount of b-actin protein of different cell extractsbetter able to clear minimum residual disease and prolong
overall survival.
By analogy to normal stem cells, CSCs are inherently
resistant to chemotherapy through mechanisms that serve
to protect stem cells from DNA and cellular damage. Firstly,
most current agents destroy rapidly proliferating cells.8
Because CSCs, like all stem cells, are relatively quiescent,
the current chemotherapeutic approaches may be inef-
fective.8 Secondly, stem cells tend to be more resistant to
chemotherapeutic agents and radiation than more mature
cell types from the same tissue are.32 This is believed to be
due to the presence of multidrug resistance, antiapoptotic
proteins, and enhanced DNA repair mechanisms.33 Since
this appears to hold true for CSCs, we would predict that
they would also display resistance to therapeutics.
Most of the knowledge of cancer gene expression was
obtained using material from whole-tumor preparations.
Establishing mechanisms of resistance to chemotherapeutic
drugs can be difficult, especially with heterogeneous
tumors. Because CSCs often make up only a tiny proportion
of all cancer cells in a tumor, their genotype may easily be
obscured by all of the other cancer cells when this meth-
odology is utilized. It is necessary to isolate the CSC
subpopulation from tumors and evaluate their gene
expression to identify molecular pathways which are crit-
ical to the CSC population. Our previous study successfully
enriched OC-SLCs, a subpopulation of CSCs, from OSCC cells
through serum-free cultivation.9 With this in vitro culture
condition which facilitates sphere formation with enhanced
tumorigenecity, the study model was established and offers
a new approach to characterizing underlying mechanisms of
drug resistance.
The nucleotide excision repair (NER) pathway seems to
be a key pathway involved in mediating resistance or
sensitivity to platinum chemotherapeutic agents.10 The NERas purified from parental OC2 cells or derived OC-SLC, and the
by reverse transcription-PCR analysis; (B) Total proteins were
by western blotting with anti-ERCC1 or anti-actin antibodies as
was referred as loading control.
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repairs DNA lesions which alter the helical structure of the
DNA molecule and interfere with DNA replication and
transcription. The ERCC1 protein plays a key role in the NER
pathway. ERCC1 dimerizes with xeroderma pigmentosum
complementation group F, and this complex is required for
the excision of damaged DNA. A large body of preclinical
evidence suggests that ERCC1 mRNA or protein expression
levels may be correlated with cisplatin resistance in human
cancer cell lines.34e36 Further studies also showed
increased sensitivity to cisplatin after antisense RNA inhi-
bition of ERCC1.37 Evaluation of ERCC1 mRNA levels in
tumor samples taken from patients in small retrospective
clinical trials of ovarian,18,19 colorectal,20 and non-small
cell lung cancers also showed an inverse correlation with
either the response to platinum therapy or survival.22 The
work we present is novel in that, not only is it the first study
showing the expression of ERCC1 in isolated CSCs, but it is
also the first study showing cisplatin resistance in the OC-
SLC subpopulation. These data imply that ERCC1 might
play a pivotal role in mediating platinum chemoresistance
in CSCs, where it acts to excise damaged DNA which would
otherwise insult these crucial stem/progenitor cells.
In conclusion, we demonstrated that OC-SLCs display
higher ERCC1 expression with the ability of enhanced
cisplatin resistance. The resistance of in vitro chemo-
therapy is partially due to preferential activation of ERCC1
gene expression. A greater understanding of the charac-
terization of the CSC population will shed new light on the
underlying biological mechanism of this specific population
and, thus, will ultimately lead to the development of
more-specific therapeutic agents for treating this deadly
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